105 related articles for article (PubMed ID: 19860831)
21. Differential regulation of the cynomolgus, human, and rat acyl-CoA oxidase promoters by PPARalpha.
Kane CD; Francone OL; Stevens KA
Gene; 2006 Oct; 380(2):84-94. PubMed ID: 16828988
[TBL] [Abstract][Full Text] [Related]
22. Involvement of microsomal fatty aldehyde dehydrogenase in the alpha-oxidation of phytanic acid.
Verhoeven NM; Jakobs C; Carney G; Somers MP; Wanders RJ; Rizzo WB
FEBS Lett; 1998 Jun; 429(3):225-8. PubMed ID: 9662422
[TBL] [Abstract][Full Text] [Related]
23. Sjögren-Larsson syndrome. Deficient activity of the fatty aldehyde dehydrogenase component of fatty alcohol:NAD+ oxidoreductase in cultured fibroblasts.
Rizzo WB; Craft DA
J Clin Invest; 1991 Nov; 88(5):1643-8. PubMed ID: 1939650
[TBL] [Abstract][Full Text] [Related]
24. An Indian family with Sjögren-Larsson syndrome caused by a novel ALDH3A2 mutation.
Sakai K; Akiyama M; Yanagi T; Nampoothiri S; Mampilly T; Sunitha V; Shimizu H
Int J Dermatol; 2010 Sep; 49(9):1031-3. PubMed ID: 20883264
[TBL] [Abstract][Full Text] [Related]
25. Sjögren-Larsson syndrome: molecular genetics and biochemical pathogenesis of fatty aldehyde dehydrogenase deficiency.
Rizzo WB
Mol Genet Metab; 2007 Jan; 90(1):1-9. PubMed ID: 16996289
[TBL] [Abstract][Full Text] [Related]
26. Fatty aldehyde dehydrogenase: genomic structure, expression and mutation analysis in Sjögren-Larsson syndrome.
Rizzo WB; Lin Z; Carney G
Chem Biol Interact; 2001 Jan; 130-132(1-3):297-307. PubMed ID: 11306053
[TBL] [Abstract][Full Text] [Related]
27. Sjogren-Larsson syndrome associated hypermelanosis.
Xu YC; Hou JQ; Zhu WJ; Li P
J Cosmet Dermatol; 2020 Apr; 19(4):789-798. PubMed ID: 31697031
[TBL] [Abstract][Full Text] [Related]
28. Fatty aldehyde and fatty alcohol metabolism: review and importance for epidermal structure and function.
Rizzo WB
Biochim Biophys Acta; 2014 Mar; 1841(3):377-89. PubMed ID: 24036493
[TBL] [Abstract][Full Text] [Related]
29. Microsomal fatty aldehyde dehydrogenase catalyzes the oxidation of aliphatic aldehyde derived from ether glycerolipid catabolism: implications for Sjögren-Larsson syndrome.
Rizzo WB; Heinz E; Simon M; Craft DA
Biochim Biophys Acta; 2000 Dec; 1535(1):1-9. PubMed ID: 11113626
[TBL] [Abstract][Full Text] [Related]
30. Disruption of the Sjögren-Larsson Syndrome Gene Aldh3a2 in Mice Increases Keratinocyte Growth and Retards Skin Barrier Recovery.
Naganuma T; Takagi S; Kanetake T; Kitamura T; Hattori S; Miyakawa T; Sassa T; Kihara A
J Biol Chem; 2016 May; 291(22):11676-88. PubMed ID: 27053112
[TBL] [Abstract][Full Text] [Related]
31. [Mechanisms of tanshinone Ⅱ_A in reducing 4-HNE-induced hepatocyte damage by activating PPARα].
Qian QY; Ying N; Yang Z; Zhou L; Liu QS; Hu ZY; Fan CL; Li ST; Dou XB
Zhongguo Zhong Yao Za Zhi; 2019 May; 44(9):1862-1868. PubMed ID: 31342714
[TBL] [Abstract][Full Text] [Related]
32. Fatty aldehyde dehydrogenase: potential role in oxidative stress protection and regulation of its gene expression by insulin.
Demozay D; Rocchi S; Mas JC; Grillo S; Pirola L; Chavey C; Van Obberghen E
J Biol Chem; 2004 Feb; 279(8):6261-70. PubMed ID: 14638678
[TBL] [Abstract][Full Text] [Related]
33. Characterisation of recombinant human fatty aldehyde dehydrogenase: implications for Sjögren-Larsson syndrome.
Lloyd MD; Boardman KD; Smith A; van den Brink DM; Wanders RJ; Threadgill MD
J Enzyme Inhib Med Chem; 2007 Oct; 22(5):584-90. PubMed ID: 18035827
[TBL] [Abstract][Full Text] [Related]
34. Fatty aldehyde dehydrogenase multigene family involved in the assimilation of n-alkanes in Yarrowia lipolytica.
Iwama R; Kobayashi S; Ohta A; Horiuchi H; Fukuda R
J Biol Chem; 2014 Nov; 289(48):33275-86. PubMed ID: 25315778
[TBL] [Abstract][Full Text] [Related]
35. Phytosphingosine degradation pathway includes fatty acid α-oxidation reactions in the endoplasmic reticulum.
Kitamura T; Seki N; Kihara A
Proc Natl Acad Sci U S A; 2017 Mar; 114(13):E2616-E2623. PubMed ID: 28289220
[TBL] [Abstract][Full Text] [Related]
36. Genomic organization and expression of the human fatty aldehyde dehydrogenase gene (FALDH).
Rogers GR; Markova NG; De Laurenzi V; Rizzo WB; Compton JG
Genomics; 1997 Jan; 39(2):127-35. PubMed ID: 9027499
[TBL] [Abstract][Full Text] [Related]
37. Genotype and phenotype variability in Sjögren-Larsson syndrome.
Weustenfeld M; Eidelpes R; Schmuth M; Rizzo WB; Zschocke J; Keller MA
Hum Mutat; 2019 Feb; 40(2):177-186. PubMed ID: 30372562
[TBL] [Abstract][Full Text] [Related]
38. A gatekeeper helix determines the substrate specificity of Sjögren-Larsson Syndrome enzyme fatty aldehyde dehydrogenase.
Keller MA; Zander U; Fuchs JE; Kreutz C; Watschinger K; Mueller T; Golderer G; Liedl KR; Ralser M; Kräutler B; Werner ER; Marquez JA
Nat Commun; 2014 Jul; 5():4439. PubMed ID: 25047030
[TBL] [Abstract][Full Text] [Related]
39. Novel ALDH3A2 mutations in structural and functional domains of FALDH causing diverse clinical phenotypes in Sjögren-Larsson syndrome patients.
Rajeshwari M; Karthi S; Singh R; Efthymiou S; Gowda VK; Varalakshmi P; Srinivasan VM; Houlden H; Keller MA; Rizzo WB; Ashokkumar B
Hum Mutat; 2021 Aug; 42(8):1015-1029. PubMed ID: 34082469
[TBL] [Abstract][Full Text] [Related]
40. Method to simultaneously determine the sphingosine 1-phosphate breakdown product (2E)-hexadecenal and its fatty acid derivatives using isotope-dilution HPLC-electrospray ionization-quadrupole/time-of-flight mass spectrometry.
Neuber C; Schumacher F; Gulbins E; Kleuser B
Anal Chem; 2014 Sep; 86(18):9065-73. PubMed ID: 25137547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
